Levothyroxine sodium (LT4) is a thyroid hormone prescribed as supplemental therapy in congenital and acquired hypothyroidism. This pathology is common in general population with an incidence of 4.1/1000 per year in women and 0.6/1000 per year in men. Though widely used, few cases of levothyroxine allergy are reported. Here we report a case of 44 year old male, who following two months of treatment initiation with L thyroxine 75 mcg, he manifested with hypersensitivity reactions progressing in form of maculopapular rash.
Keywords: Levothyroxine Sodium, Maculopapular Rash, Cutaneous Adverse Drug Reaction, Drug Sensitivity Testing.
×
How to Cite This Article
Vancouver
Mukherjee S, Samajdar SS, Sarkar A, Ghosh AK. L-Thyroxine induced maculopapular rash: A case report [Internet]. Int J Pharm Chem Anal. 2019 [cited 2025 Sep 12];6(3):85-87. Available from: https://doi.org/10.18231/j.ijpca.2019.016
APA
Mukherjee, S., Samajdar, S. S., Sarkar, A., Ghosh, A. K. (2019). L-Thyroxine induced maculopapular rash: A case report. Int J Pharm Chem Anal, 6(3), 85-87. https://doi.org/10.18231/j.ijpca.2019.016
MLA
Mukherjee, Shatavisa, Samajdar, Shambo Samrat, Sarkar, Ajanta, Ghosh, Amit K. "L-Thyroxine induced maculopapular rash: A case report." Int J Pharm Chem Anal, vol. 6, no. 3, 2019, pp. 85-87. https://doi.org/10.18231/j.ijpca.2019.016
Chicago
Mukherjee, S., Samajdar, S. S., Sarkar, A., Ghosh, A. K.. "L-Thyroxine induced maculopapular rash: A case report." Int J Pharm Chem Anal 6, no. 3 (2019): 85-87. https://doi.org/10.18231/j.ijpca.2019.016